Syntax Research, Inc. Lexicon Pharmaceuticals, Inc. Transaction History
Syntax Research, Inc.
- $141 Billion
- Q2 2025
A detailed history of Syntax Research, Inc. transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Syntax Research, Inc. holds 142 shares of LXRX stock, worth $153. This represents 0.0% of its overall portfolio holdings.
Number of Shares
142
Previous 142
-0.0%
Holding current value
$153
Previous $66,000
104.55%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding LXRX
# of Institutions
131Shares Held
196MCall Options Held
310KPut Options Held
77.3K-
Artal Group S.A. Luxembourg, N4136MShares$147 Million100.0% of portfolio
-
Black Rock Inc. New York, NY9.89MShares$10.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.56MShares$10.3 Million0.0% of portfolio
-
Schonfeld Strategic Advisors LLC New York, NY8.21MShares$8.87 Million0.03% of portfolio
-
Siren, L.L.C. New York, NY3.52MShares$3.8 Million0.09% of portfolio
About LEXICON PHARMACEUTICALS, INC.
- Ticker LXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 188,726,000
- Market Cap $204M
- Description
- Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...